CN107531804A - 嵌合蛋白 - Google Patents

嵌合蛋白 Download PDF

Info

Publication number
CN107531804A
CN107531804A CN201680021442.1A CN201680021442A CN107531804A CN 107531804 A CN107531804 A CN 107531804A CN 201680021442 A CN201680021442 A CN 201680021442A CN 107531804 A CN107531804 A CN 107531804A
Authority
CN
China
Prior art keywords
cells
cell
ser
ile
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680021442.1A
Other languages
English (en)
Chinese (zh)
Inventor
M.普莱
B.菲利普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of CN107531804A publication Critical patent/CN107531804A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680021442.1A 2015-04-13 2016-04-12 嵌合蛋白 Pending CN107531804A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506223.5A GB201506223D0 (en) 2015-04-13 2015-04-13 Chimeric protein
GB1506223.5 2015-04-13
PCT/GB2016/051019 WO2016166521A1 (en) 2015-04-13 2016-04-12 Chimeric protein

Publications (1)

Publication Number Publication Date
CN107531804A true CN107531804A (zh) 2018-01-02

Family

ID=53333686

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680021442.1A Pending CN107531804A (zh) 2015-04-13 2016-04-12 嵌合蛋白

Country Status (10)

Country Link
US (1) US10869911B2 (https=)
EP (1) EP3283526B1 (https=)
JP (1) JP6704411B2 (https=)
CN (1) CN107531804A (https=)
AU (1) AU2016250200B2 (https=)
CA (1) CA2981846A1 (https=)
ES (1) ES2749903T3 (https=)
GB (1) GB201506223D0 (https=)
HK (1) HK1243107B (https=)
WO (1) WO2016166521A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115397844A (zh) * 2019-11-21 2022-11-25 雷姆迪亚生物公司 生长因子恢复
CN115397863A (zh) * 2020-04-01 2022-11-25 基因医疗免疫疗法有限责任公司 Cd3融合蛋白及其用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
AU2019403393B2 (en) * 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
EP4199947A4 (en) 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
JP2024527882A (ja) * 2021-07-21 2024-07-26 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 新規のキメラ抗原受容体及びそれを発現する免疫細胞
AU2023400596A1 (en) * 2022-11-29 2025-06-19 Malcorp Biodiscoveries Limited Novel cd20 protein
CA3278900A1 (en) 2023-03-31 2024-10-03 AbelZeta Inc. BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000854A2 (en) * 1999-06-24 2001-01-04 Angiogene Pharmaceuticals Limited Chimeric proteins mediating targeted apoptosis
CN101583626A (zh) * 2006-10-10 2009-11-18 瓦西尼斯公司 抗cd20抗体和使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2496698T3 (en) * 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
ES2649991T3 (es) 2012-11-19 2018-01-16 Baliopharm Ag Anticuerpo biespecífico recombinante que se une a CD20 y CD95
JP2017100947A (ja) * 2014-03-31 2017-06-08 株式会社オーダーメードメディカルリサーチ 目的抗原に対する抗体の作製方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000854A2 (en) * 1999-06-24 2001-01-04 Angiogene Pharmaceuticals Limited Chimeric proteins mediating targeted apoptosis
CN101583626A (zh) * 2006-10-10 2009-11-18 瓦西尼斯公司 抗cd20抗体和使用方法
CN101583626B (zh) * 2006-10-10 2014-01-29 瓦西尼斯公司 抗cd20抗体和使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115397844A (zh) * 2019-11-21 2022-11-25 雷姆迪亚生物公司 生长因子恢复
CN115397863A (zh) * 2020-04-01 2022-11-25 基因医疗免疫疗法有限责任公司 Cd3融合蛋白及其用途

Also Published As

Publication number Publication date
ES2749903T3 (es) 2020-03-24
GB201506223D0 (en) 2015-05-27
HK1243107B (en) 2020-05-08
JP6704411B2 (ja) 2020-06-03
JP2018512154A (ja) 2018-05-17
EP3283526A1 (en) 2018-02-21
CA2981846A1 (en) 2016-10-20
US10869911B2 (en) 2020-12-22
US20180169189A1 (en) 2018-06-21
WO2016166521A1 (en) 2016-10-20
AU2016250200A1 (en) 2017-10-26
EP3283526B1 (en) 2019-09-04
AU2016250200B2 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
US11103532B2 (en) Chimeric protein
EP3283526B1 (en) Chimeric protein
JP2022058681A (ja) 受容体
HK1243107A1 (en) Chimeric protein
JP2017537622A (ja) がんを治療するための方法及び組成物
KR20190016507A (ko) TGFβRII의 프레임시프트 돌연변이체를 인식하는 T-세포 수용체
KR20210055034A (ko) 면역 이펙터 세포를 사용하여 종양을 치료하는 방법
TWI843716B (zh) hTERT特異性結合分子
CN121127488A (zh) 一种t细胞受体及其用途
HK1236005B (en) Chimeric protein
HK1236005A1 (en) Chimeric protein
EA042909B1 (ru) Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: England Atsushi

Applicant after: UCL business Limited

Address before: England Atsushi

Applicant before: UCL Business Co., Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20201125

Address after: England Atsushi

Applicant after: AUTOLUS Ltd.

Address before: England Atsushi

Applicant before: UCL business Ltd.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180102